To uncover the PTM-related molecular mechanisms driving resistance and identify new therapeutic targets for more effective treatment strategies, we further applied this approach to explore the interplay between glycoproteomic and phosphoproteomic profiles in four different non–small cell lung cancer (NSCLC) cells with sensitivity or resistance in response to the EGFR inhibitor. This evidence concerns the gene EGFR and non-small cell lung carcinoma.